Hemab Therapeutics
COAG
56 hedge funds and large institutions have $1.33B invested in Hemab Therapeutics in 2026 Q2 according to their latest regulatory filings, with 56 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
77.64% more ownership
Funds ownership: 0% → 77.64% (+78%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$215M |
| 2 |
NHAS
Novo Holdings A/S
Hellerup,
Denmark
|
+$115M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$102M |
| 4 |
Capital International Investors
Los Angeles,
California
|
+$99.4M |
| 5 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$99.4M |
Top Sellers
COAG Hedge Fund Activity: Q2 2026 in Review
56 of the 8,344 institutional investors tracked by Wall St. Rank reported a position in Hemab Therapeutics (COAG) for Q2 2026, worth a combined $1.33B.
Buyers outnumbered sellers: 56 funds opened new COAG positions and 0 closed out — a net gain of 56 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was RA Capital Management, opening a new position worth an estimated $215M.
- 56 institutional investors held Hemab Therapeutics (COAG) as of Q2 2026, up from 0 in Q1 2026.
- Funds reported $1.33B of Hemab Therapeutics stock for Q2 2026.
- 56 funds opened new Hemab Therapeutics positions in Q2 2026 and 0 closed out, a net change of +56 holders.
- The largest Hemab Therapeutics buyer in Q2 2026 was RA Capital Management, an estimated $215M added.
Based on aggregated 13F filings for Q2 2026.